Skip to content
Skip to navigation menu
10 Apr 2014
The prospect of four new cancer medicines becoming a reality for patients has taken a huge step forward with the announcement of a £34M investment by a European private biotech company in University research.
ProTide is a platform developed by Professor Chris McGuigan and his team at Cardiff University’s School of Pharmacy and Pharmaceutical Sciences. ProTides are specifically designed to bypass key cancer cell resistance pathways that limit the efficacy of so many of today’s anti-cancer drugs.
Cardiff physicists part of international team
New GW4 research fund to tackle world’s ‘grand challenges’
Largest project of its kind gets £388k funding boost from Alzheimer’s Research UK with support from Iceland Foods
New vaccine hope for leading viral cause of birth defects
Cardiff leads largest ever Alzheimer’s study
The origins of breast cancer
Psychology could hold the key to tackling climate change
This is an externally hosted beta service offered by Google.